Skip to main content
GutCited

Saccharomyces boulardii 用于 旅行者腹泻

B 证据 至少一项随机试验支持这一结论,结果基本一致。

RCT显示,若在旅行前5天开始服用,可将旅行者腹泻减少25%至40%。效果因目的地不同而异。

<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dsaccharomyces\u002Dboulardii\u0026condition\u003Dtravelers\u002Ddiarrhea'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

B

结论

RCT显示,若在旅行前5天开始服用,可将旅行者腹泻减少25%至40%。效果因目的地不同而异。

Key Study Findings

Meta-Analysis
Strain-Specific Systematic Review with Meta-Analysis of Probiotics Efficacy in the Treatment of Irritable Bowel Syndrome.
Dose: None vs: placebo Outcome: improvement in key IBS symptoms 效果: None None

研究人群: patients with IBS from 32 RCTs evaluating 10 probiotic strains

Randomized Controlled Trial n=47 8 weeks Double-blind
Effects of a polyphenol-rich extract blend, probiotics, and hydrolyzed fiber on quality of life and …
Dose: None vs: Placebo (Group I) and partial formulation (Group II) Outcome: IBS quality of life (QoL questionnaire) 效果: Dysphoria: median diff -5 (Group III) vs -1 (contr 0.0021 (dysphoria Group III)

研究人群: Patients with IBS

Other
Ibero-Latin American clinical practice guideline for the use of biotics in pediatric gastroenterology, hepatology, and …
Dose: None vs: None Outcome: Clinical guideline recommendations for pediatric GI 效果: None None

研究人群: Pediatric patients with GI disorders

Observational Study n=279
Use of Probiotics During Antibiotic Therapy in Pediatrics: A Cross-Sectional Survey of Italian Primary Care …
Dose: None vs: None Outcome: Probiotic prescribing habits of Italian PCPs 效果: L. rhamnosus GG used by 91.8% None

研究人群: Italian primary care pediatricians

Other n=70 16 weeks Open-label
Synbiotic Supplementation for Chronic Constipation in Patients Under Peritoneal Dialysis: An Italian Multicenter Prospective Study.
Dose: None vs: None (single-arm study) Outcome: Constipation scoring system change 效果: -5.3 (95% CI -5.9/-4.7) 0.001

研究人群: Peritoneal dialysis patients with chronic constipation

Review
An update on probiotics in paediatrics.
Dose: None vs: None Outcome: GI disorder outcomes in paediatrics 效果: None None

研究人群: Paediatric patients with GI disorders

Key Statistics

4

研究数量

3200

受试者

↑

Positive

B

等级

Referenced Papers

Current opinion in … 2025
Advances in experimental … 2024 2 次引用
Advances in experimental … 2019 17 次引用
The American journal … 2018 46 次引用
Pediatric gastroenterology, hepatology … 2017 42 次引用
Journal of pediatric … 2016 233 次引用
Digestive diseases (Basel, … 2016 37 次引用
The Cochrane database … 2015 233 次引用
Journal of clinical … 2015 35 次引用
Expert opinion on … 2014 57 次引用
Frontiers in immunology 2013 263 次引用
Journal of clinical … 2011 432 次引用
Journal for specialists … 2010 22 次引用
American journal of … 2010
European journal of … 2009 91 次引用
Current opinion in … 2009 82 次引用
Advances in biochemical … 2008 535 次引用
American family physician 2008
The Journal of … 2007 265 次引用
The American journal … 2001 648 次引用
International journal of … 2000 181 次引用
Clinical infectious diseases … 1998 346 次引用

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

常用剂量

general:
250-500 mg/day (equivalent to 5-10 billion CFU)
aadprevention:
500 mg/day (start with antibiotic, continue 7 days after)
cdiffprevention:
500 mg twice daily as adjunct to standard therapy
travelersdiarrhea:
250-500 mg/day starting 5 days before travel

上限: Well-tolerated up to 1,000 mg/day in clinical trials

研究中使用的剂量

剂量 持续时间 效果 N
None -- Positive --
None 8 weeks Positive 47
None -- Positive --
None -- Mixed 279
None 16 weeks Positive 70
None -- Positive --
None -- Positive --
None -- Mixed --

最佳服用时间: Can be taken with or without food; space 2 hours from antifungals

Safety & Side Effects

已报告的副作用

  • ⚠ Mild gas and bloating
  • ⚠ Rare: fungemia in critically ill patients with central venous catheters
  • ⚠ Thirst (yeast may increase water requirements)
  • ⚠ Very rare: potential environmental contamination risk in ICU settings

已知相互作用

  • ● Antifungal medications (may kill S. boulardii, reducing effectiveness)
  • ● Monoamine oxidase inhibitors (S. boulardii contains tyramine)
  • ● Immunosuppressants (theoretical risk of fungemia in immunocompromised patients)

可耐受最高摄入量: Well-tolerated up to 1,000 mg/day in clinical trials

在开始服用任何补充剂之前,请务必咨询您的医疗保健提供者。

Frequently Asked Questions

Does Saccharomyces boulardii help with 旅行者腹泻?
Based on 4 studies with 3,200 participants, there is moderate evidence from clinical studies that Saccharomyces boulardii may support 旅行者腹泻 management. Our evidence grade is B (Good Evidence).
How much Saccharomyces boulardii should I take for 旅行者腹泻?
Studies have used various dosages. A commonly studied range is 250-500 mg/day (equivalent to 5-10 billion CFU). Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Saccharomyces boulardii?
Reported side effects may include Mild gas and bloating, Rare: fungemia in critically ill patients with central venous catheters, Thirst (yeast may increase water requirements), Very rare: potential environmental contamination risk in ICU settings. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Saccharomyces boulardii and 旅行者腹泻?
We rate the evidence as Grade B (Good Evidence). This rating is based on 4 peer-reviewed studies with 3,200 total participants. The overall direction of effect is positive.

其他成分用于 旅行者腹泻

Saccharomyces boulardii 用于其他健康状况

References

  1. [1] Roman Maslennikov et al.. J Clin Med. 2026. Strain-Specific Systematic Review with Meta-Analysis of Probiotics Efficacy in the Treatment of Irritable Bowel Syndrome. doi:10.3390/jcm15031152 PubMed
  2. [2] Ailim Margarita Carías Domínguez et al.. Probiotics Antimicrob Proteins. 2025. Intestinal Dysbiosis: Exploring Definition, Associated Symptoms, and Perspectives for a Comprehensive Understanding - a Scoping Review. doi:10.1007/s12602-024-10353-w PubMed
  3. [3] Kok-Ann Gwee et al.. J Gastroenterol Hepatol. 2025. The evidence for probiotics in the treatment of digestive disorders in the pediatric population. doi:10.1111/jgh.16809 PubMed
  4. [4] Qianfang Liu et al.. Front Cell Infect Microbiol. 2025. Saccharomyces boulardii and Bifidobacterium co-treatment for antibiotic associated diarrhea in pediatrics: a multicenter efficacy and safety study. doi:10.3389/fcimb.2025.1575605 PubMed
  5. [5] Adrianna Wierzbicka et al.. Front Nutr. 2025. Effects of a polyphenol-rich extract blend, probiotics, and hydrolyzed fiber on quality of life and gut health markers in patients … doi:10.3389/fnut.2025.1603011 PubMed
  6. [6] Gennaro Argentino et al.. J Ren Nutr. 2025. Synbiotic Supplementation for Chronic Constipation in Patients Under Peritoneal Dialysis: An Italian Multicenter Prospective Study. doi:10.1053/j.jrn.2025.10.010 PubMed
  7. [7] Giacomo Biasucci et al.. Antibiotics (Basel). 2025. Use of Probiotics During Antibiotic Therapy in Pediatrics: A Cross-Sectional Survey of Italian Primary Care Pediatricians. doi:10.3390/antibiotics14060577 PubMed
  8. [8] Sylvia Cruchet et al.. Bol Med Hosp Infant Mex. 2025. Ibero-Latin American clinical practice guideline for the use of biotics in pediatric gastroenterology, hepatology, and nutrition: probiotics chapter. doi:10.24875/BMHIM.M25000043 PubMed
  9. [9] Maria Zemła et al.. Curr Opin Clin Nutr Metab Care. 2025. An update on probiotics in paediatrics. doi:10.1097/MCO.0000000000001192 PubMed
  10. [10] Vladimir Hodzhev et al.. Open Forum Infect Dis. 2024. High-dose Probiotic Mix of Lactobacillus spp., Bifidobacterium spp., Bacillus coagulans, and Saccharomyces boulardii to Prevent Antibiotic-associated Diarrhea in Adults: A … doi:10.1093/ofid/ofae615 PubMed
  11. [11] Su-Wei Zhang et al.. Zhongguo Dang Dai Er Ke Za Zhi. 2024. [A prospective randomized controlled study on probiotics for the prevention of antibiotic-associated diarrhea in infants and young children]. doi:10.7499/j.issn.1008-8830.2401129 PubMed
  12. [12] Elvira Ingrid Levy et al.. Adv Exp Med Biol. 2024. Clostridioides difficile Infections: Prevention and Treatment Strategies. doi:10.1007/978-3-031-58572-2_11 PubMed
  13. [13] Dhanasekhar Kesavelu et al.. Ther Adv Infect Dis. 2023. Current understanding of antibiotic-associated dysbiosis and approaches for its management. doi:10.1177/20499361231154443 PubMed
  14. [14] Qingrui Yang et al.. Front Pharmacol. 2023. Overview of systematic reviews of probiotics in the prevention and treatment of antibiotic-associated diarrhea in children. doi:10.3389/fphar.2023.1153070 PubMed
  15. [15] Sarath Gopalan et al.. Cureus. 2023. Unique Properties of Yeast Probiotic Saccharomyces boulardii CNCM I-745: A Narrative Review. doi:10.7759/cureus.46314 PubMed
  16. [16] Nyier W Doar et al.. Cureus. 2023. Qualitative Analysis of the Efficacy of Probiotic Strains in the Prevention of Antibiotic-Associated Diarrhea. doi:10.7759/cureus.40261 PubMed
  17. [17] Amarender S Puri. J Assoc Physicians India. 2023. The Role of Yeast Probiotics in Gastrointestinal Conditions: An Overview. doi:10.5005/japi-11001-0235 PubMed
  18. [18] Christian Boggio Marzet et al.. Arch Argent Pediatr. 2022. Approach to probiotics in pediatrics: the role of Lactobacillus rhamnosus GG. doi:10.5546/aap.2022.eng.e1 PubMed
  19. [19] Suparna Roy Sarkar et al.. Physiol Behav. 2021. Saccharomyces boulardii ameliorates gut dysbiosis associated cognitive decline. doi:10.1016/j.physbeh.2021.113411 PubMed
  20. [20] Dorota Czerucka et al.. World J Gastroenterol. 2019. Diversity of Saccharomyces boulardii CNCM I-745 mechanisms of action against intestinal infections. doi:10.3748/wjg.v25.i18.2188 PubMed
  21. [21] Konstantinos Leventogiannis et al.. Probiotics Antimicrob Proteins. 2019. Effect of a Preparation of Four Probiotics on Symptoms of Patients with Irritable Bowel Syndrome: Association with Intestinal Bacterial Overgrowth. doi:10.1007/s12602-018-9401-3 PubMed
  22. [22] Mariana L Palma et al.. Appl Microbiol Biotechnol. 2019. Genetically engineered probiotic Saccharomyces cerevisiae strains mature human dendritic cells and stimulate Gag-specific memory CD8+ T cells ex vivo. doi:10.1007/s00253-019-09842-8 PubMed
  23. [23] Meltem Dinleyici et al.. Adv Exp Med Biol. 2019. Clostridium difficile Colitis Prevention and Treatment. doi:10.1007/5584_2018_322 PubMed
  24. [24] Lynne V McFarland et al.. Front Med (Lausanne). 2018. Strain-Specificity and Disease-Specificity of Probiotic Efficacy: A Systematic Review and Meta-Analysis. doi:10.3389/fmed.2018.00124 PubMed
  25. [25] Jason C Sniffen et al.. PLoS One. 2018. Choosing an appropriate probiotic product for your patient: An evidence-based practical guide. doi:10.1371/journal.pone.0209205 PubMed
  26. [26] Cecilia Mantegazza et al.. Pharmacol Res. 2018. Probiotics and antibiotic-associated diarrhea in children: A review and new evidence on Lactobacillus rhamnosus GG during and after antibiotic treatment. doi:10.1016/j.phrs.2017.08.001 PubMed
  27. [27] Ivan D Florez et al.. PLoS One. 2018. Comparative effectiveness and safety of interventions for acute diarrhea and gastroenteritis in children: A systematic review and network meta-analysis. doi:10.1371/journal.pone.0207701 PubMed
  28. [28] Jie Chen et al.. World J Pediatr. 2018. Chinese clinical practice guidelines for acute infectious diarrhea in children. doi:10.1007/s12519-018-0190-2 PubMed
  29. [29] Ronald L Koretz. Am J Gastroenterol. 2018. Probiotics in Gastroenterology: How Pro Is the Evidence in Adults? doi:10.1038/s41395-018-0138-0 PubMed
  30. [30] Diego Currò et al.. Br J Pharmacol. 2017. Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders. doi:10.1111/bph.13632 PubMed
  31. [31] Jue-Rong Feng et al.. Eur J Clin Pharmacol. 2017. Efficacy and safety of probiotic-supplemented triple therapy for eradication of Helicobacter pylori in children: a systematic review and network meta-analysis. doi:10.1007/s00228-017-2291-6 PubMed
  32. [32] Donald Cameron et al.. World J Gastroenterol. 2017. Probiotics for gastrointestinal disorders: Proposed recommendations for children of the Asia-Pacific region. doi:10.3748/wjg.v23.i45.7952 PubMed
  33. [33] Iva Hojsak. Pediatr Gastroenterol Hepatol Nutr. 2017. Probiotics in Children: What Is the Evidence? doi:10.5223/pghn.2017.20.3.139 PubMed
  34. [34] Hania Szajewska et al.. J Pediatr Gastroenterol Nutr. 2016. Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Children. doi:10.1097/MPG.0000000000001081 PubMed
  35. [35] Heike Stier et al.. Clin Exp Gastroenterol. 2016. Influence of Saccharomyces boulardii CNCM I-745on the gut-associated immune system. doi:10.2147/CEG.S111003 PubMed
  36. [36] Stephan Ehrhardt et al.. Open Forum Infect Dis. 2016. Saccharomyces boulardii to Prevent Antibiotic-Associated Diarrhea: A Randomized, Double-Masked, Placebo-Controlled Trial. doi:10.1093/ofid/ofw011 PubMed
  37. [37] Hania Szajewska et al.. Dig Dis. 2016. Probiotic Bacterial and Fungal Strains: Claims with Evidence. doi:10.1159/000443359 PubMed
  38. [38] Joshua Z Goldenberg et al.. Cochrane Database Syst Rev. 2015. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. doi:10.1002/14651858.CD004827.pub4 PubMed
  39. [39] Lynne V McFarland. Antibiotics (Basel). 2015. Probiotics for the Primary and Secondary Prevention of C. difficile Infections: A Meta-analysis and Systematic Review. doi:10.3390/antibiotics4020160 PubMed
  40. [40] Alfredo Guarino et al.. J Clin Gastroenterol. 2015. Probiotics for Prevention and Treatment of Diarrhea. doi:10.1097/MCG.0000000000000349 PubMed
  41. [41] Danielle Barnes et al.. Nutr Clin Pract. 2015. Bugs and Guts: Practical Applications of Probiotics for Gastrointestinal Disorders in Children. doi:10.1177/0884533615610081 PubMed
  42. [42] Carlos Pérez. Nutr Hosp. 2015. [Probiotics for the treating acute diarrhea and preventing antibiotic-associated diarrhea in children]. doi:10.3305/nh.2015.31.sup1.8709 PubMed
  43. [43] Ener Cagri Dinleyici et al.. Expert Opin Biol Ther. 2014. Saccharomyces boulardii CNCM I-745 in different clinical conditions. doi:10.1517/14712598.2014.937419 PubMed
  44. [44] George Micklefield. MMW Fortschr Med. 2014. [Saccharomyces boulardii in the treatment and prevention of antibiotic-associated diarrhea]. PubMed
  45. [45] G Micklefield. MMW Fortschr Med. 2014. [Saccharomyces boulardii in the treatment and prevention of antibiotic-associated diarrhea]. PubMed
  46. [46] Angélica T Vieira et al.. Front Immunol. 2013. The role of probiotics and prebiotics in inducing gut immunity. doi:10.3389/fimmu.2013.00445 PubMed
  47. [47] Pietro Pozzoni et al.. Am J Gastroenterol. 2012. Saccharomyces boulardii for the prevention of antibiotic-associated diarrhea in adult hospitalized patients: a single-center, randomized, double-blind, placebo-controlled trial. doi:10.1038/ajg.2012.56 PubMed
  48. [48] Maria Assunta Zocco et al.. Am J Gastroenterol. 2012. Saccharomyces boulardii and antibiotic-associated diarrhea: effectiveness of prophylactic use. doi:10.1038/ajg.2012.222 PubMed
  49. [49] Ewa Kamińska. Med Wieku Rozwoj. 2012. [Effectiveness and safety of probiotics in children on the basis of clinical trials]. PubMed
  50. [50] Stefano Guandalini. J Clin Gastroenterol. 2011. Probiotics for prevention and treatment of diarrhea. doi:10.1097/MCG.0b013e3182257e98 PubMed
  51. [51] Lynne V McFarland. World J Gastroenterol. 2010. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. doi:10.3748/wjg.v16.i18.2202 PubMed
  52. [52] Jean-François Bisson et al.. Dig Dis Sci. 2010. Preventive effects of different probiotic formulations on travelers' diarrhea model in wistar rats : preventive effects of probiotics on TD. doi:10.1007/s10620-009-0822-4 PubMed
  53. [53] Kathleen Jones. J Spec Pediatr Nurs. 2010. Probiotics: preventing antibiotic-associated diarrhea. doi:10.1111/j.1744-6155.2010.00231.x PubMed
  54. [54] Nancy Toedter Williams. Am J Health Syst Pharm. 2010. Probiotics. doi:10.2146/ajhp090168 PubMed
  55. [55] Yvan Vandenplas et al.. Eur J Pediatr. 2009. Saccharomyces boulardii in childhood. doi:10.1007/s00431-008-0879-7 PubMed
  56. [56] Alfredo Guarino et al.. Curr Opin Gastroenterol. 2009. Probiotics as prevention and treatment for diarrhea. doi:10.1097/MOG.0b013e32831b4455 PubMed
  57. [57] Michael de Vrese et al.. Adv Biochem Eng Biotechnol. 2008. Probiotics, prebiotics, and synbiotics. doi:10.1007/10_2008_097 PubMed
  58. [58] Benjamin Kligler et al.. Am Fam Physician. 2008. Probiotics. PubMed
  59. [59] Shira Idit Doron et al.. J Clin Gastroenterol. 2008. Probiotics for prevention of antibiotic-associated diarrhea. doi:10.1097/MCG.0b013e3181618ab7 PubMed
  60. [60] Michael de Vrese et al.. J Nutr. 2007. Probiotics and prebiotics: effects on diarrhea. doi:10.1093/jn/137.3.803S PubMed
  61. [61] Silvia Salvatore et al.. Nutrition. 2007. Probiotics and zinc in acute infectious gastroenteritis in children: are they effective? doi:10.1016/j.nut.2007.03.008 PubMed
  62. [62] B C Johnston et al.. Cochrane Database Syst Rev. 2007. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. doi:10.1002/14651858.CD004827.pub2 PubMed
  63. [63] Lynne V McFarland. Am J Gastroenterol. 2006. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. doi:10.1111/j.1572-0241.2006.00465.x PubMed
  64. [64] Bradley C Johnston et al.. CMAJ. 2006. Probiotics for pediatric antibiotic-associated diarrhea: a meta-analysis of randomized placebo-controlled trials. doi:10.1503/cmaj.051603 PubMed
  65. [65] Jeffry A Katz. J Clin Gastroenterol. 2006. Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile diarrhea. doi:10.1097/00004836-200603000-00017 PubMed
  66. [66] Mehmet Can et al.. Med Sci Monit. 2006. Prophylactic Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea: a prospective study. PubMed
  67. [67] P R Marteau et al.. Am J Clin Nutr. 2001. Protection from gastrointestinal diseases with the use of probiotics. doi:10.1093/ajcn/73.2.430s PubMed
  68. [68] E Bergogne-Bérézin. Int J Antimicrob Agents. 2000. Treatment and prevention of antibiotic associated diarrhea. doi:10.1016/s0924-8579(00)00293-4 PubMed
  69. [69] C Högenauer et al.. Clin Infect Dis. 1998. Mechanisms and management of antibiotic-associated diarrhea. doi:10.1086/514958 PubMed
  70. [70] L V McFarland et al.. Anaerobe. 1997. Pharmaceutical probiotics for the treatment of anaerobic and other infections. doi:10.1006/anae.1996.0062 PubMed

FDA 免责声明: 这些声明未经美国食品药品监督管理局(FDA)评估。本网站上的产品和信息无意用于诊断、治疗、治愈或预防任何疾病。所展示的证据等级基于我们对已发表的同行评审研究的分析,不构成医疗建议。在开始任何补充剂方案之前,请务必咨询您的医疗保健提供者。